Objective. Melatonin is a hormone predominantly synthesized and secreted during the night by the pineal gland. Artifi cial light at night, especially its blue part, acutely suppresses the melatonin production. Th e aim of the present study was to fi nd out, whether an intense blue light phototherapy of severe hyperbilirubinemia, may suppress the melatonin production during the night when the eyes will be properly protected by a sleep mask.
Melatonin is a dark-time hormone, biosynthesized in the pineal gland exclusively during the night. Its production is under the circadian control of the master circadian oscillator localized in the hypothalamic suprachiasmatic nucleus. Th e melatonin production in the night can be eff ectively suppressed by a light (Bojkowski et al. 1987a; McIntyre et al. 1989) . Th e suppressive eff ect of the light depends on its duration, intensity, and wavelength. Th e shorter light wavelengths, corresponding to the blue light, induce stronger melatonin suppression (Brainard et al. 2008; West et al. 2011 ).
Melatonin has pleiotropic eff ects acting at diff erent levels of the human physiology (Hardeland et al. 2011) . Th erefore, the decreased melatonin production can be related to diff erent pathological situations and requires a specifi c attention.
Th e blue light therapy successfully reduces the serum bilirubin levels in the jaundiced neonates suffering from hyperbilirubinemia. Th e Crigler-Najjar syndrome type I is a recessively inherited disorder characterized by an absence of hepatic uridine 5'-diphospho-glucuronosyltransferase. Th e activity of this enzyme is essential for the conjugation and excretion of the bilirubin. Patients with this syndrome suff er from severe unconjugated hyperbilirubinemia and children are exposed to a phototherapy with an intense blue light (wavelength around 440 nm) for 10 h/day since their birth (Fox et al. 1998) .
It is not known whether eye protection during the exposure to intense blue light is suffi cient to preclude a nocturnal suppression of the melatonin production. Th erefore, the aim of this study was to establish the 6-sulphatoxymelatonin levels in urine of a young boy suff ering from the severe hyperbilirubinemia caused by the Crigler-Najjar syndrome type I treated by an intense blue light during the sleep period.
Materials and Methods
Th e nine-year old boy with the Crigler-Najjar syndrome type I was treated with an intense blue light every night since his birth. During the phototherapy, the illuminance at the position of his head in the bed was approximately 1800 lx with a dominant wavelength between 430-460 nm ( Figure 1) as measured by the illuminance spectrophotometer CL-500A, Konica Minolta, Japan. During the sleeping period, his eyes were covered by a sleep mask. Eight age-matched boys were used as a control group. Th ey were without any medication and slept in the dark.
Th e informed consent was obtained aft er detailed explanation of the study from all parents of the participating children. Th e study conformed to the code of the ethics stated in the Declaration of Helsinki.
Th e concentration of 6-sulphatoxymelatonin (aMT6s) in urine was measured for 6 days. Th e patient was exposed to blue light for three nights, next two nights was without phototherapy and the last night was exposed again to the blue light. Urine samples were collected every day immediately aft er waking up (approximately at 6:30) and at the end of the active phase at 20:00 h. Th e urine samples of the control boys were collected from the fi rst morning urine and the aft ernoon urine of the same day. All the samples were stored at -18 °C until analyzed.
Th e concentration of aMT6s in urine was determined by direct radioimmunoassay using a commercially available kit (Stockgrand Ltd, Guildford, UK) according to the manufacturer instructions. Th e samples were measured within four assays, inter-assay coeffi cients were 4.75%, 5.03% and 10.32% for low, medium, and high quality control samples, respectively. Mean intra-assay coeffi cient of variation was 11.23%. Creatinine was assayed in every sample (BioLaTest, ErbaLachema, Czech Republic). Th e results are expressed as aMT6s/creatinine (ng/mg).
Results and Discussion
Concentrations of aMT6s/creatinine in the fi rst morning urine of the blue light treated patient were in the range of control probands. In the fi rst patient urine, the aMT6s/creatinine concentrations were in the range from 86 to 200 ng/mg aft er whole night treatment with the blue light (Figure 2 A/a, c) and 87 ng/mg and 147 ng/mg aft er nights spent in the dark (Figure 2 A/b) . In the control group, the aMT6s/creatinine levels ranked from 47 to 220 ng/mg with average concentration of 100.11±27.05 ng/mg (Figure 2 B) .
As expected, the levels of the melatonin metabolite were low during the day-time. Th e average day-time concentration of aMT6s/creatinine was 3.73±0.97 ng/mg at the end of the day aft er night with phototherapy (Figure 2 A/a, c) and 4.76±0.96 ng/mg at the end of the day aft er nights spent in the dark. Mean day-time aMT6s/creatinine levels were 6.95±2.45 ng/mg in urine of the control group (Figure 2/B) . It is generally accepted that melatonin biosynthesis can be eff ectively monitored by measurement of the urinary aMT6s, which represents a predominant metabolite of melatonin (Bojkowski et al. 1987b; Graham et al. 1998) . Levels of melatonin metabolite in our study are in the line with the concentrations measured in published studies (Karasek 2004; Stebelova et al. 2015) .
Treatment of hyperbilirubinemia in neonates with intense blue light is a common practice. However, there are surprisingly very limited data regarding the eff ects of this treatment on the melatonin production. Th e suppressed melatonin concentrations and decreased expression of clock genes Bmal1 and Cry1 were observed in the jaundiced neonates (Chen et al. 2005) . Th e authors have recommended to set the time of the phototherapy to the day-time. In the present study, the young boy had to be treated during the night-time because of his daily school duties and activities. Our results demonstrated a clear day-night diff erence in the melatonin concentration, which was almost 50 times higher during the night-than the day-time.
Our data showed that when the eyes are suffi ciently protected by the sleep mask, the rhythmic melatonin production is preserved and the melatonin may fulfi ll its physiological function in the synchronization of the circadian rhythms in humans. Moreover, our study does not support any extraocular circadian phototransduction in humans (Campbell and Murphy 1998) , since the most parts of body were exposed to the intense blue light overnight. Taken together, our investigation suggests that the whole night treatment of hyperbilirubinemia with intense blue light has negligible side eff ects on the daily rhythm of the melatonin production, when the eyes are suffi ciently protected by the sleep mask.
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